%{search_type} search results

5,347 catalog results

RSS feed for this result
xi, 239 pages : illustrations (some color) ; 22 cm
  • 1. Introduction: the West, Spain and the early circulation of penicillin.- 2. Fleming in Spain: the hero, the antimicrobial and the politics of public acclaim.- 3. Manufacturing penicillin: health, industry and gender.- 4. Smuggling: The management of scarcity and trade of penicillin as a post-war commodity.- 5. Modern Times: screening antibiotics and the factory line.- 6. A new promising drug: bacteria, antibiotics and marketing.- 7. Beyond healing: antibiotic resistance and regulatory regimes as agents in the Spanish transition to democracy.- 8. Penicillin in Spain, 1940s-1980s: Circulating health, research and gender.- 9. Final reflections.
  • (source: Nielsen Book Data)9783319697178 20180219
This book reconstructs the early circulation of penicillin in Spain, a country exhausted by civil war (1936-1939), and oppressed by Franco's dictatorship. Embedded in the post-war recovery, penicillin's voyages through time and across geographies - professional, political and social - were both material and symbolic. This powerful antimicrobial captivated the imagination of the general public, medical practice, science and industry, creating high expectations among patients, who at times experienced little or no effect. Penicillin's lack of efficacy against some microbes fueled the search for new wonder drugs and sustained a decades-long research agenda built on the post-war concept of development through scientific and technological achievements. This historical reconstruction of the social life of penicillin between the 1940s and 1980s - through the dictatorship to democratic transition - explores political, public, medical, experimental and gender issues, and the rise of antibiotic resistance.
(source: Nielsen Book Data)9783319697178 20180219
Green Library
1 online resource.
  • Clinical Principles of Transfusion Medicine, 1e Quality Concepts in Transfusion Medicine Regulatory Oversight and Accreditation of Transfusion and Collection Services Whole Blood and Apheresis Donor Eligibility and Deferrals ABO and Rh Groups Common Significant Alloantibodies Pre-Transfusion Testing Indications and Dosing of Transfusion of Blood Components Non-Infectious Complications of Transfusions: Alloimmunization and Adverse Reactions Infectious Complications of Transfusion of Blood Components Transfusion Support in Emergencies Transfusion Medicine in Pediatric Settings Transfusion Medicine in Obstetrics and Prenatal Patients Transfusion Approaches in the Transplanted Patient Hematopoietic Stem Cell Collections and Cellular Therapies Therapeutic Apheresis New Concepts in Transfusion Medicine Future Challenges to Transfusion Practices.
  • (source: Nielsen Book Data)9780323544580 20180416
Offering a concise overview of transfusion medicine, including best practices for specific clinical settings, this practical resource by Dr. Robert W. Maitta covers the key information you need to know. Holistic, multidisciplinary coverage and a succinct, easy-to-read format make it essential reading for transfusion specialists, as well as practitioners in other specialties whose patients undergo blood transfusions. Covers the latest advancements in transfusion therapies, hematopoietic stem cells, infectious and non-infectious complications of transfusions, and future directions in transfusion medicine. Discusses special populations, including organ transplant patients; pediatric, obstetric, and geriatric patients; and patients undergoing emergency care. Consolidates fundamental clinical concepts and current practice of transfusion medicine into one convenient resource.
(source: Nielsen Book Data)9780323544580 20180416
1 online resource (535 p.) : ill. (some col.).
"Clinical research monitoring is a vital aspect of Good Clinical Practice (GCP). Its principles are straightforward: they are aimed at protecting those subjects that participate in the trial, and their goal is to provide reliable data that will contribute to the safety and efficacy of the intervention under study, i.e. to support the health of future subjects. However, the practical implementation of these major goals is complicated. Various mishaps have happened in recent history, and an extensive set of international rules and regulations have emerged. This book gives a thorough survey of the ethical and legal aspects of clinical research and provides a detailed guideline for implementing these aspects into the practice of studying investigational medicinal products in humans, in the European context. It can be used as a study aid for starting monitors, a reference guide for more experienced monitors, and anyone else involved in clinical research."--Publisher's website.
xiv, 347 pages : illustrations ; 23 cm
  • 1. Introduction to the Complex Connection between Cannabis Use and Psychosis, Psychotic Disorders, and Schizophreniaã ã Marc W. Manseau and Michael T. Compton 2. The Epidemiology of Cannabis Use in the United States ã ã Wilson M. Compton and Beth Han 3. The Biology of Cannabis in the Brain, and the Endocannabinoid System ã ã David Louis Atkinson and Jeff. K. Abbott 4. Psychotomimetic and Cognitive Effects of Î 9-Tetrahydrocannabinol in Laboratory Settings John D. Cahill, Swapnil Gupta, Jose Cortes-Briones, Rajiv Radhakrishnan, Mohamed Sherif, Deepak C. D'Souza 5. Psychotomimetic and Cognitive Effects of Cannabis Use in the General Population ã ã Nadia Solowij 6. Effects of Cannabis Use among those with Schizotypy ã ã Angelo B. Cedeno 7. Effects of Cannabis Use among those at Clinical High Risk for Schizophrenia ã ã Brian O'Donoghue, Meredith McHugh, Barnaby Nelson, and Patrick McGorry 8. Cannabis-Induced Psychotic Disorders ã ã Luca Pauselli 9. Synthetic Cannabinoids and Synthetic Cannabinoid-Induced Psychotic Disorders ã ã Papanti Duccio, Schifano Fabrizio, and Orsolini Laura 10. Cannabis Use as an Independent Risk Factor for, or Component Cause of, Schizophrenia and Related Psychotic Disorders ã ã Jodi M. Gilman, Sara M. Sobolewski, and Anne Eden Evins 11. Cannabis Use as a Determinant of Earlier Age at Onset of Schizophrenia and Related Psychotic Disorders ã ã Claire Ransay Wan and Beth Broussard 12. The Prevalence of Cannabis Use, and Effects on Course and Outcomes, among Individuals with Schizophrenia and Related Psychotic Disordersã ã Ana Fresan, Rebeca Robles-Garcia, and Carlos-Alfonso Tovilla-Zarate 13. The Treatment of Cannabis Use Disorders among Individuals with Psychotic Disorders ã ã Peter Bosanac, Ana Lusicic, and David J. Castle 14. Cannabidiol as a Potential Novel Therapeutic Agent for Psychotic Disorders ã ã Serena Deiana and Erica Zamberletti.
  • (source: Nielsen Book Data)9780128047910 20180423
The Complex Connection between Cannabis and Schizophrenia provides an in-depth overview of the current state of research into the role that cannabis plays in schizophrenia, covering both the pathophysiological and the pharmacological implications. It addresses the epidemiology of cannabis use and the risks associated with its use, the biological aspects of the drug, its effects on the brain and the pharmacological possibilities of using cannabidiol to treat schizophrenia. It is the only book on the market devoted exclusively to examining the links between this very commonly used (and misused) drug and a specific set of devastating psychiatric illnesses, providing a comprehensive guide to our current understandings of this relationship. Marijuana is the most commonly used illicit drug globally, and is becoming increasingly decriminalized and even legalized worldwide. Among the numerous mental-health concerns related to the drug, there is mounting evidence of an intricate link between cannabis use and schizophrenia and related psychotic disorders. At the same time, there is promising evidence to suggest that cannabidiol, one of the many compounds found in cannabis that activates the brain's cannabinoid receptors, could prove to be an effective antipsychotic to treat schizophrenia.
(source: Nielsen Book Data)9780128047910 20180423
Green Library
xii, 465 pages : illustrations ; 25 cm
  • Prologue: A new door
  • A renaissance
  • Natural history: bemushroomed
  • History: the first wave. Part I: the promise ; Part II: the crack-up
  • Travelogue: journeying underground. Trip one: LSD ; Trip two: Psilocybin ; Trip three: 5-MeO-DMT (or, the toad)
  • The neuroscience: your brain on psychedelics
  • The trip treatment: Psychedelics in psychotherapy. One: Dying ; Two: Addiction ; Three: Depression ; Coda: Going to meet my default mode network
  • Epilogue: In praise of neural diversity.
"When Michael Pollan set out to research how LSD and psilocybin (the active ingredient in magic mushrooms) are being used to provide relief to people suffering from difficult-to-treat conditions such as depression, addiction and anxiety, he did not intend to write what is undoubtedly his most personal book. But upon discovering how these remarkable substances are improving the lives not only of the mentally ill but also of healthy people coming to grips with the challenges of everyday life, he decided to explore the landscape of the mind in the first person as well as the third. Thus began a singular adventure into the experience of various altered states of consciousness, along with a dive deep into both the latest brain science and the thriving underground community of psychedelic therapists ..."-- Provided by publisher.
Green Library, Education Library (Cubberley)
AMSTUD-231X-01, EDUC-231-01, JEWISHST-291X-01, RELIGST-231X-01
ix, 136 pages ; 22 cm.
  • 1. Identity and Taboo among Paleo Dieters2. Beleaguered Bodies: Illness and Obesity in Neoliberal Australia3. Narratives of Paleo Redemption: Agency, Resistance and the Rise of Populism in Health4. The Promise and Pitfalls of Paleo.
  • (source: Nielsen Book Data)9783319672496 20180129
This book explores the cultural and economic conditions fuelling the popularity of the polarizing Paleo diet in Australia. Based on ethnographic research in Melbourne and Sydney, Catie Gressier recounts the compelling narratives of individuals struggling with illness and weight issues. She argues that `going Paleo' provides a sense of agency and means of resistance to the neoliberal policies and practices underpinning the growing prevalence of lifestyle diseases. From its nostalgic constructions of the past, to the rise of anti-elite sentiments inherent in new forms of health populism, Gressier provides a nuanced understanding of the Paleo diet's contemporary appeal.
(source: Nielsen Book Data)9783319672496 20180129
Green Library
1 online resource
  • List of Contributors Preface Table of Contents Chapter 1 Mechanisms of Oligonucleotide Actions Chapter 2 The Medicinal Chemistry of Antisense Oligonucleotides Chapter 3 Cellular Pharmacology of Antisense Oligonucleotides Chapter 4 Pharmacokinetics and Pharmacodynamics of Antisense Oligonucleotides Chapter 5 Tissue Distribution, Metabolism and Clearance Chapter 6 Hybridization-independent Effects - Principles and Specific Considerations for Oligonucleotide Drugs Chapter 7 Hybridization-Dependent Effects The Prediction, Evaluation and Consequences of Unintended Target Hybridization Chapter 8 Class-related proinflammatory effects Chapter 9 Exaggerated Pharmacology Chapter 10 Genotoxicity Tests for Novel Oligonucleotide-Based Therapeutics Chapter 11 Reproductive and Developmental Toxicity Testing Strategies for Oligonucleotide-based Therapeutics Chapter 12 Specific Considerations for Preclinical Development of Inhaled Oligonucleotides Chapter 13 Lessons Learned in Oncology Programs Chapter 14 Inhaled Antisense for Treatment of Respiratory Disease Chapter 15 Antisense oligonucleotides for treatment of neurology diseases Chapter 16 Nucleic Acids as Adjuvants Chapter 17 Splice-switching Oligonucleotides Chapter 18 CMC Aspects for the Clinical Development of Spiegelmers.
  • (source: Nielsen Book Data)9781118537336 20180709
A comprehensive review of contemporary antisense oligonucleotides drugs and therapeutic principles, methods, applications, and research Oligonucleotide-based drugs, in particular antisense oligonucleotides, are part of a growing number of pharmaceutical and biotech programs progressing to treat a wide range of indications including cancer, cardiovascular, neurodegenerative, neuromuscular, and respiratory diseases, as well as other severe and rare diseases. Reviewing fundamentals and offering guidelines for drug discovery and development, this book is a practical guide covering all key aspects of this increasingly popular area of pharmacology and biotech and pharma research, from the basic science behind antisense oligonucleotides chemistry, toxicology, manufacturing, to safety assessments, the design of therapeutic protocols, to clinical experience. Antisense oligonucleotides are single strands of DNA or RNA that are complementary to a chosen sequence. While the idea of antisense oligonucleotides to target single genes dates back to the 1970's, most advances have taken place in recent years. The increasing number of antisense oligonucleotide programs in clinical development is a testament to the progress and understanding of pharmacologic, pharmacokinetic, and toxicologic properties as well as improvement in the delivery of oligonucleotides. This valuable book reviews the fundamentals of oligonucleotides, with a focus on antisense oligonucleotide drugs, and reports on the latest research underway worldwide. Helps readers understand antisense molecules and their targets, biochemistry, and toxicity mechanisms, roles in disease, and applications for safety and therapeutics Examines the principles, practices, and tools for scientists in both pre-clinical and clinical settings and how to apply them to antisense oligonucleotides Provides guidelines for scientists in drug design and discovery to help improve efficiency, assessment, and the success of drug candidates Includes interdisciplinary perspectives, from academia, industry, regulatory and from the fields of pharmacology, toxicology, biology, and medicinal chemistry Oligonucleotide-Based Drugs and Therapeutics belongs on the reference shelves of chemists, pharmaceutical scientists, chemical biologists, toxicologists and other scientists working in the pharmaceutical and biotechnology industries. It will also be a valuable resource for regulatory specialists and safety assessment professionals and an important reference for academic researchers and post-graduates interested in therapeutics, antisense therapy, and oligonucleotides.
(source: Nielsen Book Data)9781118537336 20180709
xvi, 320 pages : illustrations (some color) ; 22 cm.
  • 1. Introduction.- 2. The Status of Patent Medicines.- 3. Constructing the Industry.- 4. Connecting the Country.- 5. Supplying the Consumer.- 6. Persuading the Poorly.- 7. Utilising the Imagination as Therapy.- 8. Harnessing the Potency of Print.- 9. The Legacy of the Patent Medicines Industry.
  • (source: Nielsen Book Data)9783319697772 20180219
In this book, the ownership, distribution and sale of patent medicines across Georgian England are explored for the first time, transforming our understanding of healthcare provision and the use of the printed word in that era. Patent medicines constituted a national industry which was largely popular, reputable and stable, not the visible manifestation of dishonest quackery as described later by doctors and many historians. Much of the distribution, promotion and sale of patent medicines was centrally controlled with directed advertising, specialisation, fixed prices and national procedures, and for the first time we can see the detailed working of a national market for a class of Georgian consumer goods. Furthermore, contemporaries were aware that changes in the consumers' `imagination' increased the benefits of patent medicines above the effects of their pharmaceutical components. As the imagination was altered by the printed word, print can be considered as an essential ingredient of patent medicines. This book will challenge the assumptions of all those interested in the medical, business or print history of the period.
(source: Nielsen Book Data)9783319697772 20180219
SAL3 (off-campus storage)
1 online resource.
  • 1. Introduction: Seriously, What is Precision Medicine? 2. Redefining Disease Causality 3. Genetics: Clues, Not Answers, to the Mysteries of Precision Medicine 4. Disease Convergence 5. The Precision of the Rare Diseases 6. Precision Organisms 7. Reinventing Diagnosis 8. Precision Data 9. Impersonalized Precision Medicine 10. The Alternate Futures of Precision Medicine.
  • (source: Nielsen Book Data)9780128143933 20180312
Despite what you may have read in the popular press and in social media, Precision Medicine is not devoted to finding unique treatments for individuals, based on analyzing their DNA. To the contrary, the goal of Precision Medicine is to find general treatments that are highly effective for large numbers of individuals who fall into precisely diagnosed groups. We now know that every disease develops over time, through a sequence of defined biological steps, and that these steps may differ among individuals, based on genetic and environmental conditions. We are currently developing rational therapies and preventive measures, based on our precise understanding of the steps leading to the clinical expression of diseases. Precision Medicine and the Reinvention of Human Disease explains the scientific breakthroughs that have changed the way that we understand diseases, and reveals how medical scientists are using this new knowledge to launch a medical revolution.
(source: Nielsen Book Data)9780128143933 20180312
ix, 122 pages ; 20 cm.
  • Table of Contents Chapter 1: A brief history of dieting Chapter 2: Being overweight or obese Chapter 3: Why do we overeat? Chapter 4: Why are we not active enough? Chapter 5: Dieting and its consequences Chapter 6: Why do diets fail? Chapter 7: Successful dieting Chapter 8: Some strategies to change behavior Chapter 9: Dieting well: making successful dieting happen Chapter 10: Helping others to lose weight - for health professionals Chapter 11: Helping others: top tips for children Chapter 12: Concluding thoughts.
  • (source: Nielsen Book Data)9781138501256 20180508
Why do some of us become overweight? Why is it so difficult to lose weight? How can we adopt healthy attitudes towards food? The Psychology of Dieting takes a broad and balanced view of the causes of weight gain and the challenges involved in dieting. Exploring the cognitive, emotional and social triggers which lead us to make poor decisions around food, the book considers what it means to diet well. By understanding our psychological selves, the book shows how we can change our unhealthy behaviours and potentially lose weight. In an era of weight problems, obesity, and dangerous dieting, The Psychology of Dieting shows us that there is no such thing as a miracle diet, and that we must understand how our minds shape the food choices we make.
(source: Nielsen Book Data)9781138501256 20180508
Green Library
1 online resource.
  • Front Cover; Quantitative Systems Pharmacology: Models and Model-Based Systems with Applications; Copyright; Contents; Contributors; Preface; Acknowledgments; Section 1: Introduction to quantitative systems pharmacology; Chapter 1: Quantitative systems pharmacology: Extending the envelope through systems engineering; 1. Introduction; 2. The emergence of QSP modeling; 2.1. Multiscale modeling: Beyond the drug target; 2.2. Modeling the disease state; 3. Modeling drug exposure and drug response at the systemic level; 4. Modeling biological and drug interactions at the molecular level
  • 4.1. Omics data4.2. Genomics; 4.3. Transcriptomics; 4.4. Proteomics; 4.5. Metabolomics; 4.6. Omics network using pathway enrichment; 4.7. Case study: Pathway enrichment for synthetic MPL; 5. Summary of the model development process; 6. QSP in context; 6.1. Case study: Cortisol regulation in the context of environmental clues: Next challenges; 7. How systems engineering can enable QSP; 8. Final comments; Acknowledgments; References; Section 2: Modeling and applications of systemic pharmacokinetics and pharmacodynamics
  • Chapter 2: An engineering oriented approach to physiologically based pharmacokinetic and pharmacodynamic modeling1. Introduction; 2. Classic compartmental pharmacokinetic models; 3. Physiologically based pharmacokinetic models; 3.1. Individualization of the pharmacokinetic prediction; 3.2. Model identification; 3.2.1. The rationale of model-assisted experiments; 3.2.2. Linearization method; 3.2.3. Monte Carlo method; 3.2.4. Bootstrap method; 3.2.5. A posteriori identifiability; 4. Introduction to pharmacodynamics; 5. Mathematical formulation of a PBPK model; 5.1. The PBPK model
  • 5.1.1. Model parameters5.1.2. PK simulation; 6. Mathematical formulation of PD models; 6.1. Direct effect model: Hill equation; 6.2. Indirect response models; 6.3. Irreversible effect models; 7. Conclusions; References; Chapter 3: Advanced Techniques for the Optimal Design of Experiments in Pharmacokinetics; 1. Introduction; 2. Identifying a physiological model: The need for experimental design; 3. Design of experiments under constraints for physiological models; 3.1. Design procedure; 3.2. Design of experimental protocols under uncertainty; 4. Case study I: Identification of a PK-PD model
  • 5. Case study II: Design of more effective clinical tests for the study of VWD6. Conclusions; References; Chapter 4: On the Identifiability of Physiological Models: Optimal Design of Clinical Tests; 1. Introduction; 2. The concept of identifiability; 3. Identifiability tests; 3.1. A priori tests for parametric identifiability; 3.2. A posteriori tests for parametric identifiability; 3.3. Practical identifiability of parametric models; 4. Identifiability in the development of compartmental models; 5. Optimal design of clinical tests for guaranteed identifiability
1 online resource.
  • 1. Population medicine versus precision medicine 2. Precision Medicine initiatives and programs 3. The role of genomics in personalized medicine 4. Small Data, Big Data, and Data Analytics 5. How Mobile Technology and EHRs can personalize healthcare 6. i2b2, SHRINE, Clinical Query, and Other Research Tools 7. Overcoming the barriers and limitations of precision medicine 8. Interoperability and Personalized Patient Care 9. Protecting patient privacy and implementing security 10. Consumer and Patient Engagement.
  • (source: Nielsen Book Data)9780128116357 20180312
Realizing the Promise of Precision Medicine: The Role of Patient Data, Mobile Technology, and Consumer Engagement explains the potential of personalized medicine and the value of those approaches in making that potential a reality. The book helps transform one-size-fits-all healthcare into a system that focuses on individual needs and the unique needs of each family member, discussing topics such as U.S. sponsored precision medicine initiative, genomics, the role of electronic health records and mobile medicine, patient engagement and empowerment, health information exchange and patient data protection. In addition, the book discusses the barriers and limitations of precision medicine and how to overcome them. Readers will find valuable insights into how big data, patient engagement, mobile technology, and genomics help individualize medical care and offer a pathway to help detect many undiscovered causes of diseases.
(source: Nielsen Book Data)9780128116357 20180312
xv, 240 pages : illustrations ; 24 cm
  • 1. Proprietary medicines and the fiscal state-- 2. The medicine stamp duty and the authority of law-- 3. The tax and the profession of pharmacy-- 4. The tax and the integrity of medicines-- 5. The demise of the tax.
  • (source: Nielsen Book Data)9781107025455 20171127
In 1783, a stamp duty was imposed on proprietary or 'quack' medicines. These largely useless but often dangerous remedies were immensely popular. The tax, which lasted until 1941, was imposed to raise revenue. It failed in its incidental regulatory purpose, had a negative effect in that the stamp was perceived as a guarantee of quality, and had a positive effect in encouraging disclosure of the formula. The book explains the considerable impact the tax had on chemists and druggists - how it led to an improvement in professional status, but undermined it by reinforcing their reputations as traders. The legislation imposing the tax was complex, ambiguous and never reformed. The tax authorities had to administer it, and executive practice came to dominate it. A minor, specialised, low-yield tax is shown to be of real significance in the pharmaceutical context, and of exceptional importance as a model revealing the wider impact of tax law and administration.
(source: Nielsen Book Data)9781107025455 20171127
SAL3 (off-campus storage)
vii, 321 pages : color illustrations ; 28 cm
Medical Library (Lane)
xiii, 210 pages : illustrations (some color), map ; 23 cm
  • Waters/cultures
  • Bathing and domination in the early modern Atlantic world
  • Policing waters and baths in eighteenth-century Mexico City
  • Enlightenment science of mineral springs
  • Groundwater and hydraulic opulence in the late nineteenth century
  • Chemistry, biology, and the heterogeneity of modern waters
  • Dispossession and bottling after the revolution
  • Spa tourism in twentieth-century Mexico
  • Virtuous waters in the twenty-first century.
At publication date, a free ebook version of this title will be available through Luminos, University of California Press's Open Access publishing program. Visit www.luminosoa.org to learn more. Virtuous Waters is the first study of mineral waters and bathing in Mexico. It traces the evolving ideas about these waters, from European contact to the present, in order to shed new light on human-environment relations in the modern world. Our relation to water is among the most urgent of global issues, as increasing scarcity and pollution threaten food shortages, deteriorating public health, and the collapse of aquatic ecosystems. Drawing on ideas from political ecology, the author brings together an analysis of the shifts in the concept of water, with a material history of environments, infrastructures and bathing. The book analyzes a range of issues concerning complex "water cultures" that have formed around Mexican groundwaters over time, and suggests that this understanding might also help us comprehend and confront the water crisis that is coming to a head in the twenty first century.
(source: Nielsen Book Data)9780520291737 20180611
Green Library
1 online resource : text file, PDF
  • Foreword Chapter 1: Inhaled proteins and peptides. Chapter 2: Inhaled insulin: More compelling than ever. Chapter 3: Inhaled therapeutic siRNA for the treatment of respiratory diseases. Chapter 4: New molecules to treat asthma and COPD. Chapter 5: Inhaled anti-cancer agents. Chapter 6: Inhaled countermeasures for respiratory tract viruses. Chapter 7: Pulmonary delivery of antibiotics for respiratory infections. Chapter 8: Inhaled liposomes. Chapter 9: Inhaled traditional Chinese medicine for respiratory diseases. Chapter 10: Bronchoprovocation tests for evaluation of drug efficacy in asthma.
  • (source: Nielsen Book Data)9781498758048 20171218
The respiratory tract has been used to deliver biologically active chemicals into the human body for centuries. However, the lungs are complex in their anatomy and physiology, which poses challenges to drug delivery. Inhaled formulations are generally more sophisticated than those for oral and parenteral administration. Pulmonary drug development is therefore a highly specialized area because of its many unique issues and challenges. Rapid progress is being made and offers novel solutions to existing treatment problems. Advances in Pulmonary Drug Delivery highlights the latest developments in this field.
(source: Nielsen Book Data)9781498758048 20171218
1 online resource (x, 226 pages) : illustrations.
  • 1. Alcohol a double-edged sword: Health benefits with moderate consumption but a health hazard with excess alcohol intake 2. Drugs of abuse: An overview 3. Designer drugs including bath salts and spices 4. Combined alcohol and drug abuse: A potentially deadly mix 5. Link between environmental factors, personality factors, and addiction 6. Genetic polymorphisms of alcohol metabolizing enzymes associated with protection from or increased risk of alcohol abuse 7. Pharmacogenomics of abused drugs 8. Association between polymorphisms in genes encoding various receptors, transporters, and enzymes and alcohol/drug addiction 9. Methods of alcohol measurement 10. Laboratory methods for measuring drugs of abuse in urine 11. Analysis of drugs of abuse in serum, hair, oral fluid, sweat, and meconium.
  • (source: Nielsen Book Data)9780128054550 20170313
Alcohol, Drugs, Genes and the Clinical Laboratory provides an overview and quick reference to genetic relationships and clinical laboratory information related to the serious public health issue of alcohol and drug abuse. Written in a clear and concise manner, this book discusses the necessary information for health and safety professionals working in public health to learn about complex issues quickly to better help their patients, employees, and others affected by alcohol and drug abuse. Alcohol, Drugs, Genes and the Clinical Laboratory covers the important aspects of drugs and alcohol abuse including genetic aspects along with laboratory methods for analysis of alcohol and abused drugs with emphasis on false positive test results. The book is helpful to healthcare professionals, such as pathologists who oversee alcohol and drug testing, emergency room physicians, family practice physicians who are first healthcare professionals who identify patients susceptible to drug and alcohol abuse, and psychiatrists involved with drug and alcohol rehabilitation programs. It will also be useful to safety professionals who have to assess individuals for workplace responsibilities, ranging from police and recruitment to occupational safety and occupational medicine and public health officials.
(source: Nielsen Book Data)9780128054550 20170313
1 online resource
The definitive guide to the myriad analytical techniques available to scientists involved in biotherapeutics research Analytical Characterization of Biotherapeutics covers all current and emerging analytical tools and techniques used for the characterization of therapeutic proteins and antigen reagents. From basic recombinant antigen and antibody characterization, to complex analyses for increasingly complex molecular designs, the book explores the history of the analysis techniques and offers valuable insights into the most important emerging analytical solutions. In addition, it frames critical questions warranting attention in the design and delivery of a therapeutic protein, exposes analytical challenges that may occur when characterizing these molecules, and presents a number of tested solutions. The first single-volume guide of its kind, Analytical Characterization of Biotherapeutics brings together contributions from scientists at the leading edge of biotherapeutics research and manufacturing. Key topics covered in-depth include the structural characterization of recombinant proteins and antibodies, antibody de novo sequencing, characterization of antibody drug conjugates, characterization of bi-specific or other hybrid molecules, characterization of manufacturing host-cell contaminant proteins, analytical tools for biologics molecular assessment, and more. Each chapter is written by a recognized expert or experts in their field who discuss current and cutting edge approaches to fully characterizing biotherapeutic proteins and antigen reagentsCovers the full range of characterization strategies for large molecule based therapeuticsProvides an up-to-date account of the latest approaches used for large molecule characterizationChapters cover the background needed to understand the challenges at hand, solutions to characterize these large molecules, and a summary of emerging options for analytical characterization Analytical Characterization of Biotherapeutics is an up-to-date resource for analytical scientists, biologists, and mass spectrometrists involved in the analysis of biomolecules, as well as scientists employed in the pharmaceuticals and biotechnology industries. Graduate students in biology and analytical science, and their instructors will find it to be fascinating and instructive supplementary reading.
(source: Nielsen Book Data)9781119053101 20170731
1 online resource (xxi, 570 pages) : illustrations.
  • Anti-Aging Drugs: Where are We and Where are We Going? / Alexander M. Vaiserman and Oleh V. Lushchak
  • Aging: Natural or Disease? A View from Medical Textbooks / S. Janac, B. Clarke and D. Gems
  • The Search for the "Anti-Aging Pill": A Critical Viewpoint / Éric le Bourg
  • Testing of Geroprotectors in Experiments on Cell Cultures: Pros and Cons / Alexander N. Khokhlov and Galina V. Morgunova
  • Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development / Ramón Cacabelos, Juan Carlos Carril and Oscar Teijido
  • Nanotechnology in Anti-Aging: Nutraceutical Delivery and Related Applications / Anila Mathew, Francesco Marotta and D. Sakthi Kumar
  • Hormetins as Drugs for Healthy Aging / Suresh I. S. Rattan
  • Antioxidant Therapy of Aging: From Free Radical Chemistry to Systems Theory of Reliability / V. K. Koltover
  • Mitochondria-Targeted Rechargeable Antioxidants as Potential Anti-Aging Drugs / Elena G. Pasyukova, Boris A. Feniouk and Vladimir P. Skulachev
  • Mimetics of Caloric Restriction / Oleh Lushchak and Dmytro Gospodaryov
  • Allosteric SIRT1 Activators as Putative Anti-Aging Drugs / Basil P. Hubbard
  • Therapeutic Potential of Sirtuin Inhibitors in Cancer / Francisco Javier Alcain, Consuelo M. Nieva, Lucía Fernández del Río, Raquel Santiago-Mora, Elena Gutiérrez-Casado, Mario Duran-Prado and Jose M. Villalba
  • Lifespan-Extending Effect of Resveratrol and Other Phytochemicals / Shin-Hae Lee and Kyung-Jin Min
  • Extending Lifespan by Inhibiting the Mechanistic Target of Rapamycin (mTOR) / Dudley W. Lamming
  • mTOR, Aging and Cancer: Prospects for Pharmacological Interventions / Z. D. Sharp
  • Anti-Aging Action of PPARs: Potential Therapeutic Targets / Ki Wung Chung, Byung Pal Yu and Hae Young Chung
  • Antidiabetic Biguanides as Anti-Aging Drugs / Vladimir N. Anisimov
  • S-Adenosylmethionine Metabolism: A Promising Avenue in Anti-Aging Medicine? / W. A. M. Loenen
  • Melatonin as a Geroprotector: Healthy Aging vs. Extension of Lifespan / R. Hardeland
  • Short Peptides Regulate Gene Expression, Protein Synthesis and Enhance Life Span / Vladimir Khavinson and Irina Popovich
  • HDAC Inhibitors: A New Avenue in Anti-Aging Medicine / E. G. Pasyukova and A. M. Vaiserman
  • Human Life Extension: Opportunities, Challenges, and Implications for Public Health Policy / Ilia Stambler.
Provides an overview of current research aimed to search for life-extending medications and describes pharmacological aspects of anti-aging medicine. Readers are introduced to the historical background of geroprotection in the first chapter. In-depth information on models for investigating geroprotective drugs precedes a section covering anti-aging properties of pharmaceutical compounds, such as calorie restriction mimetics, autophagy inducers, senolytics and mitochondrial antioxidants. Finally, strategies to translate discoveries from aging research into drugs and healthcare policy perspectives on anti-ageing medicine are provided to give a complete picture of the field.
1 online resource (xvii, 456 pages)
  • Preface xvi Abacacavir (Ziagen) 435 Abacavir + Lamivudine + Dolutegravir (Triumeq) 381 Acyclovir (Zovirax) 442 Adefovir (Hepsera) 187 Albendazole (Albenza) 3 Amikacin (Amikin) 9 Amoxicillan 11 Amoxicillin-Clavulanate (Augmentin, Augmentin 600ES, Augmentin XR) 32 Amphotericin B (Fungizone) 169 Amphotericin B Colloidal Dispersion ABCD (Amphotec) 13 Amphotericin B Lipid Complex (Abelcet) 1 Ampicillin 15 Ampicillin-Sulbactam (Unasyn) 394 Anidulafungin (Eraxis) 149 Artemether/Lumefantrine (Coartem) 92 Artesunate 27 Atazanavir (Reyataz) 317 Atazanavir + Cobicistat (Evotaz) 152 Atovaquone (Mepron) 240 Atovaquone/Proguanil (Malarone) 230 Azithromycin (Zithromax, Zmax) 437 Aztreonam (Azactam) 40 Bedaquiline (Sirturo) 337 Benznidazole 51 Bithionol (Bitin) 57 Capreomycin (Capastat) 62 Caspofungin (Cancidas) 60 Cefaclor 66 Cefadroxil (Duricef) 135 Cefamandole (Mandol) 232 Cefazolin (Ancef) 18 Cefdinir (Omnicef) 270 Cefditoren Pivoxil (Spectracef) 343 Cefepime (Maxipime) 234 Cefixime (Suprax) 357 Cefotaxime (Claforan) 87 Cefotetan (Cefotan) 70 Cefoxitin (Mefoxin) 256 Cefpirome (Broact, Cefir, Cefrom, Keiten) 58 Cefpodoxime (Vantin) 406 Ceftaroline fosamil (Teflaro) 365 Ceftazidime (Tazicef, Fortaz ) 165 Ceftazidime and avibactam (Avycaz) 38 Ceftibuten (Cedax) 64 Ceftizoxime (Cefizox) 68 Ceftolozane and Tazobactam (Zerbaxa) 433 Ceftriaxone (Rocephin) 329 Cefuroxime (Zinacef, Ceftin) 72 Cephalexin (Keflex) 212 Chloramphenicol (Chloromycetin) 78 Chloroquine Phosphate (Aralen) 24 Cidofovir (Vistide) 425 Ciprofloxacin (Cipro) 83 Clarithromycin (Biaxin) 52 Clindamycin (Cleocin) 89 Clofazimine (Lamprene) 220 Cobicistat (Tybost) 390 Colistimethate Sodium (Coly-Mycin) 96 Cycloserine (Seromycin) 335 Daclatasvir (Daklinza) 112 Dalbavancin (Dalvance) 114 Dapsone 116 Daptomycin (Cubicin) 107 Darunavir (Prezista) 293 Darunavir + Cobicistat (Prezcobix) 290 Dasabuvir + Ombitasvir + Paritaprevir + Ritonavir (Viekira Pak) 415 Delamanid (Deltyba) 120 Dicloxacillin 124 Diethyl carbamazine/DEC (Hetrazan) 189 Dolutegravir (Tivicay) 375 Doripenem (Doribax) 130 Doxycycline (Vibramycin, Doryx) 132 Efavirenz (Sustiva) 359 Eflornithine (Ornidyl) 274 Elbasvir and Grazoprevir (Zepatier) 431 Elvitegravir (Vitekta) 427 Emtricitabine (Emtriva) 141 Enfuvirtide (Fuzeon) 174 Entecavir (Baraclude) 45 Ertapenem (Invanz) 201 Erythromycin 150 Ethambutol Hydrochloride (Myambutol) 248 Ethionamide (Trecator) 379 Etravirine (Intelence) 196 Famciclovir (Famvir) 157 Fidaxomicin (Dificid) 126 Fluconazole (Diflucan) 127 Flucytosine (Ancobon) 21 Fosamprenavir (Lexiva) 227 Foscarnet (Foscavir) 167 Fosfomycin (Monurol) 246 Ganciclovir Capsules and IV (Cytovene) 106 Gemifloxacin (Factive) 155 Gentamicin (Garamycin) 176 Griseofulvin (Grifulvin V, Grisovulvin, Gris-Peg) 183 Hydroxychloroquine Imipenem-Cilastatin Sodium (Primaxin) 299 Interferon Alpha (Infergen, Intron A) 193 Iodoquinol (Yodoxin) 429 Isavuconazole (Cresemba) 105 Isoniazid 205 Itraconazole (Sporanox) 345 Ivermectin (Stromectol) 353 Kanamycin (Kantrex) 210 Ketoconazole 214 Lamivudine (Epivir) 145 Lamivudine plus Abacavir (Epzicom) 147 Ledipasvir + Sofosbuvir (Harvoni) 185 Levofloxacin (Levaquin) 224 Linezolid (Zyvox) 445 Liposomal Amphotericin B (Ambisome) 7 Lopinavir/Ritonavir (Kaletra) 207 Maraviroc (Selzentry) 333 Mefloquine Hydrochloride (Lariam) 222 Meglumine Antimonite (Glucantime) 182 Melarsoprol B (Mel-B) 238 Meropenem (Merrem) 242 Metronidazole (Flagyl) 159 Micafungin (Mycamine) 250 Miltefosine (Impavido) 191 Minocycline (Minocin, Dynacin) 137 Moxifloxacin (Avelox) 35 Nafcillin 255 Neomycin (Neo-Fradin, Neomycin) 259 Nevirapine (Viramune) 418 Niclosamide (Yomesan) 430 Nifurtimox (Lampit) 219 Nitazoxanide (Alinia) 5 Nitrofurantoin (Furadantin, Macrobid, Macrodantin) 172 Ofloxacin (Floxin) 162 Ombitasvir + Paritaprevir + Ritonavir (Technivie) 363 Oritavancin (Orbactive) 272 Oseltamivir (Tamiflu) 361 Oxacillin 275 Oxamniquine (Vansil) 405 Para-aminosalicylate Sodium (Paser) 277 Peginterferon alpha-2a (Pegasys) 279 Peginterferon alpha-2b (Pegintron) 282 Penicillin (Benzathine Penicillin, Penicillin G, Penicillin V, Procaine Penicillin) 47 Pentamidine (NebuPent, Pentam) 257 Peramivir (Rapivab) 311 Piperacillin (Pipracil) 285 Piperacillin-Tazobactam (Zosyn) 440 Polymixin B Sulfate (Polymixin B) 288 Posaconazole (Noxafil) 264 Praziquantel (Biltricide) 55 Primaquine Phosphate (Primaquine) 298 Pyrantel Pamoate (Antiminth) 23 Pyrazinamide 304 Pyrimethamine (Daraprim) 118 Quinacrine HCl (Atabrine) 28 Quinidine 306 Quinine 308 Raltegravir (Isentress) 203 Ribavirin inhaled (Virazole) 421 Ribavirin oral (Copegus, Rebetol, Ribasphere) 102 Rifabutin (Mycobutin) 252 Rifampin (Rifadin) 320 Rifampin + Isoniazid (Rifamate) 323 Rifampin + Isoniazid + Pyrazinamide (Rifater) 326 Rifapentine (Priftin) 296 Rifaximin (Xifaxan) 427 Rilpivirine (Edurant) 139 Ritonavir (Norvir) 261 Simeprevir (Olysio) 268 Sofosbuvir (Sovaldi) 341 Sofosbuvir + Velpatasvir (Epclusa) 143 Spectinomycin (Trobicin) 387 Spiramycin (Rovamycine) 331 Stibogluconate (Pentostam) 284 Streptomycin 348 Sulfadiazine 355 Suramin Sodium (Germanin) 181 Tedizolid (Sivextro) 339 Telavancin (Vibativ) 413 Telbivudine (Tyzeka) 392 Tenofovir + Emtricitabine + Elvitegravir + Cobicistat (Stribild) 350 Tenofovir + Emtricitabine + Rilpivirine (Complera) 100 Tenofovir Alafenamide + Emtricitabine (Discovy) 122 Tenofovir Alafenamide + Emtricitabine + Elvitegravir + Cobicistat (Genvoya) 178 Tenofovir Alafenamide+ Emtricitabine + Rilpivirine (Odefsey) 266 Tenofovir Alafenamide fumarate (TAF) (Vemlidy) 408 Tenofovir and Emtricitabine (Truvada) 388 Tenofovir Disoproxil Fumarate (Viread) 423 Tenofovir/Emtricitabine/Efavirenz (Atripla) 29 Terbinafine (Lamisil) 217 Tetracycline Hydrochloride 367 Thiabendazole (Mintezole) 244 Ticarcillin-Clavulanate (Timentin) 371 Tigecycline (Tigacyl) 369 Tinidazole (Tindamax) 373 Tobramycin 377 Trimethoprim (Proloprim) 302 Trimethoprim/Sulfamethoxazole (Bactrim, Septra) 42 Valacyclovir (Valtrex) 399 Valganciclovir (Valcyte) 396 Vancomycin-Intravenous 403 Vancomycin-PO (Vancocin) 401 Voriconazole (Vfend) 410 Zanamivir (Relenza) 313 Zidovudine (Retrovir) 315 Zidovudine plus Lamivudine (Combivir) 98 Zidovudine, Lamivudine, and Abacavir (Trizivir) 384 Helpful Formulas, Equations, and Definitions 449 Selected Antimicrobial Toxicities 450 Selected Antimicrobial Coverage 453 Bibliography and References 456.
  • (source: Nielsen Book Data)9781119220756 20171009
A comprehensive compendium of all commonly used antibiotics, including indications, side effects, dosage information, and drug/food interactions Antibiotics Manual: A Guide to Commonly Used Antimicrobials, Second Edition is a unique, user-friendly guide made for all who prescribe antibiotics. It s the only book available that takes a 100% drug-listed approach to 200 of the most common antibiotics prescribed to patients each day. Presented in full color, it s also a convenient reference for every clinician to consult once the decision to use a particular antibiotic has been reached. This edition of Antibiotics Manual includes newer antibiotics that have been released since the publication of the First Edition and updates prescribing information for the older antibiotics. This all-new Second Edition: Has a color-coded interior design which provides quick and easy point of care access for the userIncludes 200 of the most commonly prescribed antibiotics, listed by both brand and generic namesFeatures important recently-released antibiotics such as ceftaroline, tedizolid, and bedaquiline Antibiotics Manual: A Guide to Commonly Used Antimicrobials, Second Edition is a welcome book for physicians in all specialties of medicine who prescribe antibiotics. It is also a handy tool for pharmacists, nurses, nurse practitioners, and physician assistants who want more information on the drugs they administer.
(source: Nielsen Book Data)9781119220756 20171009